Service
Spravato Treatment in Manhasset, NY: Depression Care Built Around What Standard Prescriptions Couldn't Finish
An FDA-approved nasal spray for adults whose depression hasn't lifted under standard antidepressant medications. Delivered without needles. Covered by most commercial insurance plans for eligible patients. Two nearby Nassau County offices.
Where Standard Depression Care Tends to Reach Its Limits
Every version of outpatient depression care has an implicit stopping point. The prescribing algorithm is well-defined for the first three or four medication trials, and then it starts to thin out. Beyond that threshold, the honest clinical territory becomes narrower — augmentation strategies, off-label combinations, the same monoamine mechanisms rearranged in slightly different ways. For a meaningful group of patients, that entire second-line landscape produces marginal gains at best. Clinical work published by the Johns Hopkins Medicine Department of Psychiatry and Behavioral Sciences documents what patients in this group already sense: depression that persists across multiple monoamine-based trials frequently signals that meaningful recovery requires a treatment operating through the glutamate system rather than the neurotransmitter pathways the field has spent decades refining.
Spravato treatment in Manhasset was developed for that exact clinical group. Our board-certified team at Anxiety & Depression Psychiatry provides this FDA-approved nasal spray from both of our Nassau County offices, and Manhasset patients evaluating intravenous options in parallel can review our ketamine therapy service in Manhasset at the same time. For patients cross-referencing federal-level clinical resources, the National Institutes of Health publishes accessible information on depression care, interventional options, and clinical research pathways.
Our clinical model is a full psychiatric practice, not a stand-alone Spravato provider. Spravato treatment in Manhasset, NY sits inside a wider treatment framework that adapts to your history rather than routing you through a predetermined workflow.
Explaining Spravato Without the Clinical Shorthand
Spravato is the brand name for esketamine, a psychiatric medication the FDA approved in March 2019 as the first nasal spray developed specifically for adults with treatment-resistant depression. A subsequent 2020 approval extended its clinical use to adults living with major depressive disorder alongside active suicidal ideation.
What makes Spravato mechanically different from every oral antidepressant patients typically arrive with is the target. SSRIs, SNRIs, tricyclics, and atypical antidepressants all engage the monoamine network, which means any resulting improvement builds from receptor-level adjustments that take weeks to unfold. Spravato takes a fundamentally different route. It binds NMDA receptors within the glutamate system, prompting a rapid rise in neuroplasticity, which is the underlying process the brain uses to build new neural connections and reorganize damaged pathways.
An accessible way to picture it: an oral antidepressant is like sending a repair crew that arrives eight weeks after the initial call. Spravato acts closer to same-day dispatch. Patients pursuing a Spravato treatment clinic in Manhasset typically notice a real clinical shift within the first few days rather than waiting through another two-month trial window.
The administration itself removes several of the practical obstacles that keep patients from considering interventional care. Nothing gets injected. Nothing gets infused. No new pill enters your medication list.
The Trial Data That Supports the Approvals
Neither of Spravato’s FDA approvals came through casually. Both required large randomized controlled trials in which the medication had to outperform placebo in patients whose depression had already failed at least two adequate antidepressant trials. That’s a strict bar few psychiatric medications reach.
TRANSFORM-2 was the pivotal short-term trial. Patients starting Spravato alongside a newly initiated oral antidepressant improved significantly more than those on the same oral antidepressant with a placebo nasal spray, and the difference held across primary endpoints. Response often appeared within the opening 24 hours — an onset timeline no oral antidepressant class comes close to.
SUSTAIN-1, published in JAMA Psychiatry, tackled the durability question. Patients who discontinued Spravato relapsed at significantly higher rates than those who continued on maintenance dosing. That finding is what shapes the maintenance framework contemporary Spravato programs follow.
Points worth carrying with you:
- Fresh synaptic connections form quickly in mood-regulating brain regions after dosing
- Meaningful response often emerges within hours rather than weeks
- The medication supports recovery of neural pathways worn down by prolonged illness
- Sustained improvement over time depends on structured maintenance dosing
For accessible clinical background on rapid-acting antidepressants and their role in modern care, the Cornell University Weill Cornell Medicine Department of Psychiatry publishes patient-oriented material.
Who Spravato Is Cleared to Help in Manhasset
Because Spravato holds FDA approval for a specific, narrowly defined set of psychiatric conditions, its safety framework and insurance coverage remain more consistent than most off-label options. Our clinical use follows those indications:
Treatment-Resistant Depression
The clinical definition applies when at least two adequate antidepressant trials have failed to produce meaningful improvement. Spravato was engineered specifically around this scenario.
Major Depressive Disorder with Suicidal Thoughts
The 2020 approval added coverage for adults living with major depression alongside active suicidal thoughts. The speed of Spravato’s response can meaningfully help stabilize risk while longer-term interventions build effect.
Patients whose primary condition sits outside these indications — including anxiety disorders, PTSD, OCD, and bipolar depression — may benefit more from IV ketamine, which our practice also provides. The consultation is where the appropriate path gets identified honestly.
The Actual Sequence of Treatment
Spravato treatment in Manhasset, NY runs on a structured process designed to feel predictable from the first phone call through long-term maintenance.
01.
Initial Consultation
The first appointment gives us the space to hear your treatment history in full. We’re less interested in a diagnostic label than in the clinical detail behind it: what you’ve tried, how each option performed, where the current medication regimen fits, and what a real improvement would look like for you. If Spravato doesn’t seem like the right match, we say so directly.
02.
Insurance Verification
Insurance coverage is one of Spravato’s most concrete advantages over IV ketamine. Because the FDA specifically approved it for treatment-resistant depression, most commercial insurance plans authorize coverage for patients who meet clinical criteria. Our team runs the verification process, submits prior authorization when required, and confirms expected out-of-pocket costs before any session is scheduled.
03.
Preparing for Your First Session
Before your appointment:
- Avoid eating for two hours before your treatment
- Arrange transportation home (you cannot drive after treatment)
- Wear comfortable clothing
- Plan to be at our office for approximately two and a half hours
04.
Your Treatment Session
When you arrive, we’ll check your blood pressure and review any questions you have. Then you’ll settle into a comfortable chair in our private treatment room.
Administering Spravato is straightforward. You’ll use the nasal spray device yourself while we supervise. It’s similar to using an over-the-counter nasal spray for allergies. The actual administration takes only a few minutes.
After you take Spravato, you’ll remain in our office for a two-hour observation period. This is required by the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, which governs how Spravato is dispensed and administered. During this time, we monitor your blood pressure and mental status at regular intervals.
Many patients bring headphones and listen to calming music during the observation period. Some people feel relaxed or slightly disconnected during this time. Others simply rest. The effects are temporary and typically fade within an hour or two.
05.
After Your Treatment
By the end of the observation period, most patients feel clear-headed and ready to leave. However, you cannot drive yourself home. The effects of Spravato can impair your ability to drive safely, and you should not drive until the next day after a restful night’s sleep.
Plan to take it easy for the remainder of the treatment day. Avoid making important decisions, operating heavy machinery, or engaging in activities that require full alertness.
06.
Treatment Schedule and Maintenance
Induction Phase (Weeks 1-4): You’ll receive Spravato twice weekly during the first month. This intensive initial phase allows the treatment to build momentum and establish new neural pathways.
Consolidation Phase (Weeks 5-8): Treatment typically decreases to once weekly during the second month.
Maintenance Phase (Week 9 and beyond): Most patients continue with treatments once weekly or every two weeks. The exact frequency depends on your individual response. We’ll work with you to find the schedule that keeps you feeling your best while minimizing the time commitment.
Long Island Location
Anxiety & Depression Psychiatry
300 Old Country Rd, Suite 351 Mineola, NY 11501
(646) 830-0131help@tomerlevin.comOffice Hours: Monday to Friday: 8am – 5pm
Our Mineola location is convenient to Garden City, Westbury, and central Nassau County. We’re close to NYU Winthrop Medical Center and Northwell Health’s Long Island Jewish Medical Center and Zucker Hillside Hospital.
What Differentiates Our Approach to Spravato
Board-Certified Psychiatrists
Our clinicians trained in psychiatry as their primary specialty, which shapes how Spravato treatment gets delivered here. Diagnostic clarity comes first. Complex psychiatric histories — treatment-resistant depression, comorbid anxiety, bipolar features, PTSD — are what we work with daily. That specialization is a large part of what makes us the best Spravato treatment in Westbury for adults with layered histories.
Full-Service Psychiatric Practice
Spravato produces better outcomes when it sits inside a coordinated treatment plan. We manage the surrounding pieces in-house — psychotherapy referrals, oral antidepressant adjustment, TMS if it becomes relevant, IV ketamine if Spravato doesn’t produce sufficient response. Patients don’t get sent elsewhere when the plan needs to shift.
Insurance Navigation Support
Managing insurance approvals while managing depression is a genuinely bad combination. Our staff handles benefits verification, prior authorization, appeals when needed, and financial expectations before you sit down for the first session.
REMS-Certified Provider
Spravato is only dispensed through the FDA’s Risk Evaluation and Mitigation Strategy program, which enforces strict safety protocols for administration and observation. Our practice is fully REMS-certified, meaning every safety, storage, and monitoring standard the federal program requires is in place.
Comfortable, Private Environment
Every Spravato session takes place in a private treatment room designed for your comfort. You’ll have space to relax during the two-hour observation period with access to comfortable seating, calming music options, and a peaceful atmosphere. Our medical team monitors you throughout while respecting your privacy.
Thinking Through Spravato vs. IV Ketamine
Both options are available at our Long Island offices, and both play distinct clinical roles. The right choice depends on your case rather than which one sounds stronger in isolation.
Spravato (Esketamine Nasal Spray)
FDA-approved specifically for treatment-resistant depression. Insurance coverage available for most qualifying patients. Self-administered nasal spray, no needles. Twice weekly during induction, then weekly or every two weeks. Required two-hour observation after each session. Use limited to FDA-approved indications.
IV Ketamine
Off-label use for depression, anxiety, PTSD, OCD, and related conditions. Typically not covered by insurance and billed at $600 per infusion at our practice. Administered intravenously by our medical team. Six sessions across two to three weeks during induction. Broader clinical applications beyond treatment-resistant depression. May help patients who don’t respond adequately to Spravato.
Many patients begin with Spravato because of insurance coverage. If Spravato doesn’t produce sufficient response, IV ketamine remains a viable next option. Others prefer IV ketamine from the start because they’re treating conditions outside Spravato’s FDA approval. Your consultation is where we walk through which path fits best.
Frequently Asked Questions
How quickly does Spravato work?
Many patients register a clinical shift within the first 24 to 72 hours after their opening session. For some, it takes two or three sessions before the full effect registers. Either way, the response window is dramatically shorter than the timeline expected with oral antidepressants.
Is Spravato safe?
Yes, when administered inside the REMS framework by trained clinicians. The most common short-term effects are mild dissociation, some sedation, and a brief rise in blood pressure — all of which get monitored during the two-hour observation.
How many Spravato treatments will I need?
The typical structure is twice weekly for the first four weeks, once weekly for four weeks after that, then once weekly or once every two weeks for maintenance. Total duration is guided by your response and how well the improvement holds.
What does Spravato treatment feel like?
Most patients describe a calm, slightly dreamlike quality with some mild dissociation. It doesn’t feel like being drunk, and it isn’t recreational. Effects generally clear within one to two hours.
Can I drive after Spravato treatment?
No. You’ll need someone to drive you home, and the restriction extends through the rest of the day and evening. You shouldn’t drive again until the following morning after full sleep.
How can I tell if this is the best Spravato treatment clinic in Manhasset for my situation?
The consultation is the most reliable way to find out. We’ll walk through your history, review what’s already been tried, and give you a straight read on whether our clinical setup fits. If it doesn’t, we’ll tell you what does.
Can I continue my current antidepressant?
Yes, and in fact you should. Spravato is always used alongside an oral antidepressant, not as a replacement. The FDA approval was based on studies where patients took both Spravato and an oral antidepressant together. We’ll coordinate with your prescribing physician to ensure your overall treatment plan is optimized.
Who qualifies for Spravato?
Spravato is approved for adults with treatment-resistant depression, defined as not responding adequately to at least two different antidepressants taken at adequate doses for adequate duration. It’s also approved for adults with major depression who have suicidal thoughts or behaviors. During your consultation, we’ll review your treatment history to determine whether you meet the criteria.
Do I need a referral?
No referral is required. However, because Spravato must be used alongside an oral antidepressant, coordination with your current prescribing physician is important. We encourage communication between all members of your healthcare team.
What if Spravato doesn't work for me?
Not everyone responds to Spravato, just as not everyone responds to any given treatment. If Spravato doesn’t provide adequate relief, we have other options. IV ketamine works through similar mechanisms but may help some patients who don’t respond to Spravato. TMS therapy offers a completely different, non-medication approach. Because we’re a full-service psychiatric practice, we can adjust your treatment plan without you needing to start over somewhere else.
The Case for Making the Call
You’ve already spent years working through medication after medication, adjusting doses, switching combinations, and hoping the next attempt would land. That persistence isn’t wasted. What may be worth reconsidering is the assumption that another oral option will produce a fundamentally different result. Spravato works through a different biological system, delivers as a nasal spray, and is covered by most commercial insurance plans.
Spravato treatment in Manhasset, NY may be the option that finally moves the trajectory. Our board-certified team will help you determine whether it fits your case and walk you through every step of what treatment actually looks like.
Call (646) 830-0131 to schedule a consultation. We’ll answer your questions honestly and lay out your options clearly. No pressure, and everything you share stays confidential.
Recovery doesn’t have to keep looking like the last several attempts.
Monday – Friday, 8am – 5pm Board-certified psychiatrists • Insurance coverage available • Two Long Island locations
insight
Explore Latest Insights from Us
book appointment
Let's Start Your Journey Back
(646) 830-0131help@tomerlevin.com
Mon - Fri: 8am to 5pmSat - Sun: Closed